Abstract
Glycosylation, linking the glycan chains to protein or lipid, is the most common and complex post-translational modifications of proteins. One of the important functions of glycoprotein is to maintain the ordered social life of each cell in multicellular organisms. Glycosylation is sensitive to the biochemical environment leading to the alteration of glycan chains under the physiological condition and specific diseases such as cancer. Cancer and other lethal diseases cannot be diagnosed at early stage due to classic biomarker’s low sensitivity and specificity. Recently, the development of glycan profiling technologies has offered great promises for understanding the complex glycan structures and has increased interest in applying this technology for cancer studies. In this regard, to identify the glycans as the potential biomarkers of cancer has become an important direction for clinical cancer diagnosis. This paper summarizes the current research on validating and developing of the glycans as new cancer biomarkers and the nascent field of glycomics
Keywords: Cancer biomarker, glycomics, N-glycan, oligosaccharide, personalized medicine, public health pharmacogenomics.
Current Pharmacogenomics and Personalized Medicine
Title:Validation and Development of N-glycan as Biomarker in Cancer Diagnosis
Volume: 11 Issue: 1
Author(s): Wei Wang
Affiliation:
Keywords: Cancer biomarker, glycomics, N-glycan, oligosaccharide, personalized medicine, public health pharmacogenomics.
Abstract: Glycosylation, linking the glycan chains to protein or lipid, is the most common and complex post-translational modifications of proteins. One of the important functions of glycoprotein is to maintain the ordered social life of each cell in multicellular organisms. Glycosylation is sensitive to the biochemical environment leading to the alteration of glycan chains under the physiological condition and specific diseases such as cancer. Cancer and other lethal diseases cannot be diagnosed at early stage due to classic biomarker’s low sensitivity and specificity. Recently, the development of glycan profiling technologies has offered great promises for understanding the complex glycan structures and has increased interest in applying this technology for cancer studies. In this regard, to identify the glycans as the potential biomarkers of cancer has become an important direction for clinical cancer diagnosis. This paper summarizes the current research on validating and developing of the glycans as new cancer biomarkers and the nascent field of glycomics
Export Options
About this article
Cite this article as:
Wang Wei, Validation and Development of N-glycan as Biomarker in Cancer Diagnosis, Current Pharmacogenomics and Personalized Medicine 2013; 11 (1) . https://dx.doi.org/10.2174/1875692111311010008
DOI https://dx.doi.org/10.2174/1875692111311010008 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strategies for the Preparation of Bifunctional Gadolinium(III) Chelators
Current Organic Synthesis Immunology Behind Tumors: A Mini Review
Current Cancer Therapy Reviews Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Hydrogen Sulfide-Based Anti-Inflammatory and Chemopreventive Therapies: An Experimental Approach
Current Pharmaceutical Design Interaction Between Arsenic Trioxide and Human Primary Cells: Emphasis on Human Cells of Myeloid Origin
Inflammation & Allergy - Drug Targets (Discontinued) Diosmetin Induces Cell Apoptosis by Regulating CYP1A1/CYP1A2 Due to p53 Activation in HepG2 Cells
Protein & Peptide Letters From Bone Marrow Transplantation to Cellular Therapies: Possible Therapeutic Strategies in Managing Autoimmune Disorders
Current Pharmaceutical Design Fabrication of Poly Hydroxybutyrate-Polyethylene Glycol-Folic Acid Nanoparticles Loaded by Paclitaxel
Current Drug Delivery Quinone-Based Drugs: An Important Class of Molecules in Medicinal Chemistry
Medicinal Chemistry Prediction of Breast Cancer Using Machine Learning
Recent Advances in Computer Science and Communications Recent Developments of Steroid Sulfatase Inhibitors as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Nanoparticle Therapy for Allergic and Inflammatory Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Genetic Techniques for Pharmacogenetic Analyses
Current Pharmaceutical Design Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Inorganic Nanoparticles for In Vitro Cancer Diagnosis: A Patent Review
Recent Patents on Nanomedicine Recombinant Adeno-associated Virus 9-mediated Expression of Kallistatin Suppresses Lung Tumor Growth in Mice
Current Gene Therapy Synthesis and Urease Inhibitory Activity of Some 5-Aminomethylene Barbituric/Thiobarbituric Acid Derivatives
Letters in Drug Design & Discovery Use of the Bradykinin Agonist, Cereport as a Pharmacological Means of Increasing Drug Delivery to the CNS
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Recombinant Human Serum Albumin Fusion Proteins and Novel Applications in Drug Delivery and Therapy
Current Pharmaceutical Design The Wnt Pathway: Emerging Anticancer Strategies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)